Journal of Thrombosis and Thrombolysis

, Volume 45, Issue 1, pp 51–55 | Cite as

Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge

  • Amanda N. Basto
  • Nathan P. Fewel
  • Kim Vo
  • Eileen M. Stock
  • Mia Ta


The objective of this project was to compare the time from initiation of oral anticoagulation to hospital discharge between warfarin and direct oral anticoagulants (DOACs) for the treatment of acute venous thromboembolism (VTE). This retrospective observational study was done at a single VA medical center. A total of 107 patients were included, with 42 patients (39%) in the DOAC group, which included rivaroxaban, dabigatran, and apixaban, and 65 patients (61%) in the warfarin group. Variables collected through chart review included comorbid conditions, time from initiation of oral anticoagulation to discharge, emergency department (ED) visits and readmission within 30 or 90 days, and bleeding events. The DOAC group had a shorter time to discharge compared to the warfarin group (28 vs. 114 h, p < 0.001). There were similar 30 and 90-day hospital readmission rates and/or ED visits for DOACs (23.8 and 33.3%) compared to warfarin (18.5 and 30.8%), including those related to bleeding of any severity (11.9% for DOACs vs. 9.2% for warfarin; p = 0.75). There was one major bleeding event in the DOAC group and two in the warfarin group. The use of DOACs for the treatment of acute VTE in hospitalized patients was associated with shorter time to hospital discharge when compared to warfarin.


Anticoagulation Warfarin DOAC Venous thromboembolism Length of stay 



This work was completed with support from the Central Texas Veterans Health Care System. The views expressed are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.


There was no source of funding for this study.

Compliance with ethical standards

Conflict of interest

Amanda N. Basto, Nathan P. Fewel, Kim Vo, Eileen M. Stock and Mia Ta declares that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

The local institutional review board waived the requirement of informed consent for this study.


  1. 1.
    Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352CrossRefPubMedGoogle Scholar
  2. 2.
    Badreldin H, Nichols H, Rimsans J, Carter D (2017) Evaluation of anticoagulation selection for acute venous thromboembolism. J Thromb Thrombol 43(1):74–78CrossRefGoogle Scholar
  3. 3.
    Bookhart BK, Haskell L, Bamber L et al (2014) Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. J Med Econ 10:691–695CrossRefGoogle Scholar
  4. 4.
    Matsuo H, Prins M, Lesning AWA, Fujinuma EW, Miiyamoto Y, Kajikawa M (2015) Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Curr Med Res Opin 31(6):1057–1061CrossRefPubMedGoogle Scholar
  5. 5.
    Weeda ER, Kohn CG, Peacock WF et al (2016) Rivaroxaban versus heparin bridging to warfarin therapy: impact on hospital length of stay and treatment costs for low-risk patients with pulmonary embolism. Pharmacotherapy 36(10):1109–1115CrossRefPubMedGoogle Scholar
  6. 6.
    Van Bellen B, Bamber L, Correa de Carvalho F et al (2014) Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 30(5):829–837CrossRefPubMedGoogle Scholar
  7. 7.
    Margolis JM, Deitelzweig S, Kline J et al (2016) Shorter hospital stays and lower costs for rivaroxaban compared with warfarin for venous thrombosis admissions. J Am Heart Assoc 5:e003788. doi: 10.1161/JAHA.116.003788 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, For the Subcommittee on Control of Anticoagulation (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119–2126CrossRefPubMedGoogle Scholar
  9. 9.
    Schulman S, Kearon C, The Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:392–694. doi: 10.1111/j.1538-7836.2005.01204.x Google Scholar
  10. 10.
    Roberts KM, Knight TB, Padilla-Tolentino E, Murthy M, Peterson EJ (2015) Length of stay comparison between rivaroxaban and warfarin in the treatment of pulmonary embolism: results from a real-world observational cohort study. Thrombosis. doi: 10.1155/2015/414523 PubMedPubMedCentralGoogle Scholar
  11. 11.
    Dasta JF, Pilon D, Mody SH et al (2015) Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy. Thromb Res 135:303–310CrossRefPubMedGoogle Scholar
  12. 12.
    Coleman CI, Baugh C, Crivera C et al (2017) Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism. J Med Econ 20(2):200–203. doi: 10.1080/13696998.2016.1243544 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2017

Authors and Affiliations

  • Amanda N. Basto
    • 1
  • Nathan P. Fewel
    • 1
  • Kim Vo
    • 2
  • Eileen M. Stock
    • 3
  • Mia Ta
    • 1
  1. 1.Department of Veterans AffairsCentral Texas Veterans Health Care SystemTempleUSA
  2. 2.Oregon State University/Oregon Health & Sciences University College of PharmacyPortlandUSA
  3. 3.Department of Veterans AffairsCooperative Studies Program Coordinating CenterPerry PointUSA

Personalised recommendations